The pattern, pharmacotherapy course, drug-drug interactions, and clinical outcome of COVID-۱۹ in kidney transplant patients at a referral transplantation hospital in Iran: A retrospective, observational study

Kidney transplant recipients are at higher risk of developing coronavirus disease ۲۰۱۹ (COVID-۱۹). The aim of this study was to evaluate the pattern, pharmacotherapy, drug interactions, and clinical outcome of COVID-۱۹ in kidney transplant recipients at a referral center in Iran. This retrospective, observational study was conducted in Abu Ali Sina Organ transplantation center in Shiraz, Iran. All adult kidney transplant patients diagnosed with COVID-۱۹ and hospitalized for at least ۴۸ hours were included. Required data were collected by reviewing medical charts and health information system of patients at hospital. Potential drug-drug interactions were identified using Lexi-Interact online as well as the Liverpool interactions online website. A total of ۱۰۸ patients were included. Fever, cough, and shortness of breath were the most common clinical symptoms. About three-fourth (۷۴%) of patients had non-severe COVID-۱۹. Remdesivir was the most widely used antiviral agent. mTOR inhibitors and anti-metabolites were either dose reduced or discontinued in ۱۰۰% and ۸۰.۲% of cases, respectively. Age (odds ratio [OR] = ۱.۰۶, ۹۵% [Cl] = ۱.۰۲-۱.۰۹), calcineurin inhibitor adjustment (OR = ۰.۲۶, ۹۵% Cl = ۰.۰۹-۰.۷۵), baseline white blood cell count (OR = ۱.۱۳, ۹۵% Cl = ۱.۰۱-۱.۲۸), baseline serum lactate dehydrogenase level (OR = ۱.۳۲, ۹۵% Cl = ۱.۰۳-۱.۶۹), administration of tocilizumab (OR = ۰.۰۶, ۹۵% Cl = ۰.۰۷-۰.۵۴), and the severity of COVID-۱۹ disease (OR = ۰.۰۳, ۹۵% Cl = ۰.۰۰-۰.۰۳) had significant association with mortality.  The present investigation found that COVID-۱۹ infection in kidney transplant patients may be severe and require hospitalization and even, critical care.

کلیدواژه ها:

Kidney Transplantation ، COVID ۱۹ ، pharmacotherapy ، Drug Interactions